Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes

Infection and Immunity

Volumn 72, Issue 6, 2004, Pages 3444-3450

  Mannam, Praveen ^a,c   Jones, Kevin F ^a,b   Geller, Bruce L ^a  

^a OREGON STATE UNIVERSITY   (United States)

^b SIGA Technologies Incorporated   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G; LACTOCOCCUS LACTIS C REPEAT REGION VACCINE; LL CRR VACCINE; M PROTEIN; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; LACTOCOCCUS LACTIS; MORTALITY; MOUSE; NONHUMAN; PHARYNGITIS; PRIORITY JOURNAL; PROTECTION; SALIVA LEVEL; SEROTYPE; STREPTOCOCCUS PYOGENES; SURVIVAL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; FEMALE; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; LACTOCOCCUS LACTIS; MICE; PHARYNGITIS; SALIVA; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; VACCINES, SYNTHETIC;

EID: 2542622189     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.72.6.3444-3450.2004     Document Type: Article

References (55)

1. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1994. Current protocols in molecular biology. John Wiley and Sons, New York, Inc.
2. Bessen, D., and V. A. Fischetti. 1988. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect. Immun. 56:2666-2672.
3. Bessen, D., and V. A. Fischetti. 1988. Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A. J. Exp. Med. 167:1945-1950.
4. Bessen, D., and V. A. Fischetti. 1988. Role of non-opsonic antibody in protection against group A streptococcal infection, p. 493-502. In L. Lasky (ed.), Technology advances in vaccine development. Alan R. Liss, New York, N.Y.
5. Bessen, D., and V. A. Fischetti. 1990. Synthetic peptide vaccine against mucosal colonization by group A streptococci. J. Immunol. 145:1251-1256.
6. Bouvet, J.-P., and V. A. Fischetti. 1999. Diversity of antibody-mediated immunity at the mucosal barrier. Infect. Immun. 67:2687-2691.
7. Brandtzaeg, P. 1996. History of oral tolerance and mucosal immunity. Ann. N. Y. Acad. Sci. 778:1-27.
8. Breese, B. B., and C. B. Hall. 1978. Beta hemolytic streptococcal diseases, p. 238. Houghton Mifflin, Boston, Mass.
9. Challacombe, S. J. 1983. Salivary antibodies and systemic tolerance in mice after oral immunization with bacterial antigens. Ann. N. Y. Acad. Sci. 409:177-192.
10. Challacombe, S. J., D. Rahman, H. Jeffery, S. S. Davis, and D. T. O'Hagan. 1992. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology 76:164-168.
11. Chamberlain, L., J. M. Wells, K. Robinson, K. Schofield, and R. Le Page. 1997. Mucosal immunization with recombinant Lactococcus lactis, p. 83-106. In G. Pozzi and J. M. Wells (ed.), Gram-positive bacteria as vaccine vehicles for mucosal immunization. Landes Bioscience, Austin, Tex.
12. Enouf, V., P. Langella, J. Commissaire, J. Cohen, and G. Corthier. 2001. Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic. Appl. Environ. Microbiol. 67:1423-1428.
13. Facklam, R., B. Beall, A. Efstratiou, V. Fischetti, D. Johnson, E. Kaplan, P. Kriz, M. Lovgren, D. Martin, B. Schwartz, A. Totolian, D. Bessen, S. Hollingshead, F. Rubin, J. Scott, and G. Tyrrell. 1999. emm typing and validation of provisional M types for group A streptococci. Emerg. Infect. Dis. 5:247-253.
14. Fischetti, V. A., R. D. Horstmann, and V. Pancholi. 1995. Location of the complement factor H binding site on streptococcal M6 protein. Infect. Immun. 63:149-153.
15. Fischetti, V. A., W. M. Hodges, and D. E. Hruby. 1989. Protection against streptococcal pharyngeal colonization with a vaccinia:M protein recombinant. Science 244:1487-1490.
16. Fluckiger, U., K. F. Jones, and V. A. Fischetti. 1998. Immunoglobulins to group A streptococcal surface molecules decrease adherence to and invasion of human pharyngeal cells. Infect. Immun. 66:974-979.
17. Gebert, A., H. J. Rothkotter, and R. Pabst. 1996. M cells in Peyer's patches of the intestine. Int. Rev. Cytol. 167:91-159.
18. Geller, B. L., N. Wade, T. D. Gilberts, D. E. Hruby, R. Johanson, and L. Topoisirovic. 2001. Surface expression of the conserved C repeat region of streptococcal M6 protein within the Pip bacteriophage receptor of Lactococcus lactis. Appl. Environ. Microbiol. 67:5370-5376.
19. Gerritse, K., M. Posno, M. M. Schellenkens, W. J. A. Boersma, and E. Claassen. 1990. Oral administration of TNP-Lactobacillus conjugates in mice: a model for evaluation of mucosal and systemic immune responses and memory formation elicited by transformed lactobacilli. Res. Microbiol. 141:955-962.
20. Grangette, C., H. Muller-Alouf, D. Goudercourt, M.-C. Geoffroy, M. Turneer, and A. Mercenier. 2001. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect. Immun. 69:1547-1553.
21. Hochman, N., Z. Zakay-Rones, H. Shohat, P. Ever-Hadani, J. Ehrlich, M. Schesinger, and A. Morag. 1998. Antibodies to cytomegalo and Epstein-Barr viruses in human saliva and gingival fluid. New Microbiol. 21:131-139.
22. Horstmann, R. D., H. J. Sievertsen, J. Knobloch, and V. A. Fischetti. 1988. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein Factor H. Proc. Natl. Acad. Sci. USA 85:1657-1661.
23. Iwaki, M., N. Okahashi, I. Takahashi, T. Kanamoto, Y. Sugita-Konishi, K. Aibara, and T. Koga. 1990. Oral immunization with recombinant Streptococcus lactis carrying the Streptococcus mutans surface protein antigen gene. Infect. Immun. 58:2929-2934.
24. + group A streptococci: correlation with resistance to phagocytosis. J. Immunol. 128:1897-1902.
25. Jones, K. F., B. N. Manjula, K. H. Johnston, S. K. Hollingshead, J. R. Scott, and V. A. Fischetti. 1985. Location of variable and conserved epitopes among the multiple serotypes of streptococcal M protein. J. Exp. Med. 161:623-628.
26. Jones, K. F., S. A. Khan, B. W. Erickson, S. K. Hollingshead, J. R. Scott, and V. A. Fischetti. 1986. Immunochemical localization and amino acid sequence of cross-reactive epitopes within the group A streptococcal M6 protein. J. Exp. Med. 164:1226-1238.
27. Jones, K. F., S. K. Hollingshead, J. R. Scott, and V. A. Fischetti. 1988. Spontaneous M6 protein size mutants of group A streptococci display variation in antigenic and opsonogenic epitopes. Proc. Natl. Acad. Sci. USA 85:8271-8275.
28. Jones, K. F., and V. A. Fischetti. 1988. The importance of the location of antibody binding on the M6 protein for opsonization and phagocytosis of group A M6 streptococci. J. Exp. Med. 167:1114-1123.
29. Lamm, M. E. 1997. Interaction of antigens and antibodies at mucosal surfaces. Annu. Rev. Microbiol. 51:311-340.
30. Lancefield, R. C. 1962. Current knowledge of the type specific M antigens of group A streptococci. J. Immunol. 89:307-313.
31. Lee, M. H., Y. Roussel, M. Wilks, and S. Tabaqchali. 2001. Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine 19:3927-3935.
32. Lee, S. F., S. A. Halperin, H. Wang, and A. MacArthur. 2002. Oral colonization and immune responses to Streptococcus gordonii expressing a pertussis toxin S1 fragment in mice. FEMS Microbiol. Lett. 208:175-178.
33. Lodics, T. A., and L. R. Steenson. 1993. Phage-host interactions in commercial mixed-strain dairy starter cultures: practical significance-a review. J. Dairy Sci. 76:2380-2391.
34. Medaglini, D., G. Pozzi, T. P. King, and V. A. Fischetti. 1995. Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization. Proc. Natl. Acad. Sci. USA 92:6868-6872.
35. Medina, E., and C. A. Guzman. 2001. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 19:1573-1580.
36. Mercenier, A., H. Muller-Alouf, and C. Grangette. 2000. Lactic acid bacteria as live vaccines. Curr. Issues Mol. Biol. 2:17-25.
37. Mowat, A. M. 1985. The role of antigen recognition and suppressor cells in mice with oral tolerance to ovalbumin. Immunology 56:253-260.
38. Norton, P. M., H. W. G. Brown, J. M. Wells, A. M. Macpherson, P. W. Wilson, and R. W. F. Le Page. 1996. Factors affecting the immunogenicity of tetanus toxin fragment C expressed in Lactococcus lactis. FEMS Immunol. Med. Microbiol. 14:167-177.
39. Oggioni, M. R., D. Medaglini, T. Maggi, and G. Pozzi. 1999. Engineering the Gram-positive cell surface for construction of bacterial vaccine vectors. Methods 19:163-173.
40. Pouwels, P. H., R. J. Leer, M. Shaw. M. J. Heijne den Bak-Glashouwer, F. D. Tielen, E. Smit, B. Martinez, J. Jore, and P. L. Conway. 1998. 1998. Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. Int. J. Food Microbiol. 41:155-167.
41. Pruksakorn, S., A. Galbraith, R. A. Houghten, and M. F. Good. 1992. Conserved T and B cell epitopes on the M protein of group A streptococci: induction of bactericidal antibodies. J. Immunol. 149:2729-2735.
42. Ribeiro, L. A., V. Azevedo, Y. Le Loir, S. C. Oliveira, Y. Dieye, J.-C. Piard, A. Gruss, and P. Langella. 2002. Production and targeting of the Brucella abortus antigen L7/L12 in Lactococcus lactis: a first step towards food-grade live vaccines against brucellosis. Appl. Environ. Microbiol. 68:910-916.
43. Robinson, K., L. M. Chamberlain, K. M. Schofield, J. M. Wells, and R. W. F. Le Page. 1997. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat. Biotechnol. 15:653-657.
44. Russell, M. W., Z. Moldoveanu, P. L. White, G. J. Sibert, J. Mestecky, and S. M. Michalek. 1996. Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin B subunit. Infect. Immun. 64:1272-1283.
45. Scheppler, L., M. Vogel, A. W. Zuercher, M. Zuercher, J.-E. Germond, S. M. Miescher, and B. M. Stadler. 2002. Recombinant Lactobacillus johnsonii as a mucosal vaccine delivery vehicle. Vaccine 20:2913-2920.
46. Shaw, D. M., B. Gaerthe, R. J. Leer, J. G. M. M. Van Der Stap, C. Smittenaar, M.-J. Heijne Den Bak-Glashouwer, J. E. R. Thole, F. J. Tielen, P. H. Pouwels, and C. E. G. Havenith. 2000. Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli. Immunology 100:510-518.
47. Stevens, D. L. 1995. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg. Infect. Dis. 1:69-78.
48. Strobel, S., A. M. Mowat, H. E. Drummond, M. G. Pickering, and A. Ferguson. 1983. Immunological responses to fed protein antigens in mice. II. Oral tolerance for CMI is due to activation of cyclophosphamide-sensitive cells by gut-processed antigen. Immunology 49:451-456.
49. Thole, J. E. R., P. J. van Dalen, C. E. G. Havenith, P. H. Pouwels, J. F. M. L. Seegers, F. D. Tielen, M. D. van der Zee, N. D. Zegers, and M. Shaw. 2000. Live bacterial delivery systems for development of mucosal vaccines. Curr. Opin. Mol. Ther. 2:94-99.
50. Vadolas, J., J. K. Davies, P. J. Wright, and R. A. Strugnell. 1995. Intranasal immunization with liposomes induces strong mucosal immune responses in mice. Eur. J. Immunol. 25:969-975.
51. Wagner, D. K., M. L. Clements, C. B. Reimer, M. Snyder, D. L. Nelson, and B. R. Murphy. 1987. Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J. Clin. Microbiol. 25:559-562.
52. Wells, J. M., K. Robinson, L. M. Chamberlain, K. M. Schofield, and R. W. F. Le Page. 1996. Lactic acid bacteria as vaccine delivery vehicles. Antonie Leeuwenhoek 70:317-330.
53. Wells, J. M., P. W. Wilson, P. M. Norton, M. J. Gasson, and R. W. F. Le Page. 1993. Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Mol. Microbiol. 8:1155-1162.
54. Wold, A. E., U. I. H. Dahlgren, L. A. Hanson, I. Mattsby-Baltzer, and T. Midvetdt. 1989. Difference between bacterial and food antigens in mucosal immunogenicity. Infect. Immun. 57:2666-2673.
55. Xin, K.-Q., Y. Hoshino, Y. Toda, S. Igimi, Y. Kojima, N. Jounai, K. Ohba, A. Kushiro, M. Kiwaki, K. Hamajima, D. Klinman, and K. Okuda. 2003. Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood 102:223-228.